BRAINTREE, Mass. and
BOCA RATON, Fla., March 5, 2015 /PRNewswire/ -- Haemonetics
Corporation (NYSE: HAE) and CSL Plasma, Inc. announced today that
CSL Plasma, Inc. has selected Haemonetics' Next Generation Donor
Management System ("NextGen DMS"), an innovative software
application for the management of plasma collection, as its future
system for managing more than 100 plasma donation centers across
the U.S. and Europe. The two
companies completed a significant long-term technology agreement
for a fully integrated software system designed to enable greater
efficiency and to advance the collection operations performance.
Haemonetics had previously announced that it had completed a
long-term contract with an un-named customer for the customization
of its new plasma donor management software during fiscal 2016, for
use in the customer's collection facilities in the future.
Today's announcement identified CSL Plasma, Inc. as that
customer.
"At CSL Plasma, our success is achieved through innovation and
we recognize the power of technology to seamlessly integrate and
streamline all aspects of our plasma collection activities and
equipment," explained Randy Furby,
General Manager of CSL Plasma. "We are excited to extend our
innovation strategy by partnering with Haemonetics to rollout their
NextGen DMS software across our collection network to bring us to
the next level of a truly integrated solution."
"We are excited that CSL Plasma shares our vision and we are
confident that the combination of our leading strengths will be
welcomed by the plasma industry," commented Pete Allen, President of Global Plasma for
Haemonetics. "This strategic global partnership will help us expand
the capabilities of our advanced solutions for the industry, which
includes an enhancement to our current plasma collection device
that will support two-way data communication, and will complement
our new software offering."
Haemonetics and CSL Plasma share the vision that Haemonetics'
software and device integration is the next key phase to improving
plasma collection operational efficiency. Haemonetics will
continue to work closely with the entire plasma collection industry
to meet its current and future needs, remaining focused on
innovative offerings and global partnerships.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated
to providing innovative blood management solutions for our
customers. Together, our devices and consumables, information
technology platforms, and consulting services deliver a suite of
business solutions to help our customers improve patient care and
reduce the cost of healthcare for blood collectors, hospitals, and
patients around the world. Our technologies address important
medical markets: blood and plasma component collection, the
surgical suite, and hospital transfusion services. To learn
more about Haemonetics, visit the web site www.haemonetics.com.
ABOUT CSL PLASMA
CSL Plasma, Inc. operates as a collector of human blood plasma
for use in manufacturing life-saving biotherapies and is one of the
world's largest collectors of human plasma. CSL Plasma, Inc.
has plasma collection centers in the U. S. and Germany, state-of-the-art testing laboratories
that features some of the most advanced technology, instrumentation
and automation in the field; three logistics centers and corporate
headquarters in Boca Raton,
Florida.
CSL Plasma, Inc. operates as a subsidiary of CSL Behring LLC,
headquartered in King of Prussia, Pennsylvania. CSL Behring
is a member of the CSL Group of companies. Its parent company, CSL
Limited (ASX:CSL), is headquartered in Melbourne, Australia. To learn
more about CSL Plasma, visit the web site www.cslplasma.com.
CONTACT:
Gerry Gould,
VP-Investor Relations
Tel. (781) 356-9402
gerry.gould@haemonetics.com
Alt. (781) 356-9613
Logo - http://photos.prnewswire.com/prnh/20150128/172006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/haemonetics-and-csl-plasma-announce-a-long-term-plasma-collection-software-agreement-300045884.html
SOURCE Haemonetics Corporation